An assistant's crawler fetches the page once, without running JavaScript, and reads the text, the structured data and the links. This is that view of celecor.com, from the copy the scanner kept.
characters of text without JavaScript
structured data for the business
of 3 AI crawlers turned away at the edge
Title: Home - CeleCor Therapeutics · language en-US. First 1,800 of 2,002 characters:
Home - CeleCor Therapeutics Skip to content Primary Menu Home About zalunfiban(Disaggpro™ ) Clinicaldevelopment CeleBratetrial results About us News Follow us Download Backgrounder Home About zalunfiban (Disaggpro™) Clinical development CeleBrate trial results About us News Follow us Download Backgrounder Every moment counts when treating a patient with a heart attack. About zalunfiban Zalunfiban is an investigational next-generation GPIIb/IIIa platelet inhibitor that was specifically designed for pre-hospital treatment of STEMI heart attacks and is injected subcutaneously (under the skin). Zalunfiban reaches maximal effect within 15 minutes and its antiplatelet effect wears off in about two hours. 1[1] Bentur OS, et al. Assessing the Pharmacodynamics of RUC-4 (zalunfiban), a Novel αIIbβ3 Antagonist, Using VerifyNow Assays in Patients with ST-Segment Elevation Myocardial Infarction (STEMI) Treated with Aspirin and Ticagrelor [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 1). About zalunfiban Zalunfiban is an investigational agent; it has not been approved for any use and its safety and efficacy have not been established. Addressing the time-to-treatment gap Potential for rapid heart attack treatment in multiple pre-PCI settings About Us Each year, 800,000 people in the United States have an acute myocardial infarction (AMI), or heart attack. We founded CeleCor Therapeutics to improve the treatment of ST-Segment Elevated Myocardial Infarctions (STEMI heart attacks) at the first point of medical contact. More about us CeleCor Headquarters 1155 Camino Del Mar Suite 481 Del Mar, CA, 92014 contact@celecor.com ©2026 CeleCor Therapeutics, All Rights Reserved. Home About zalunfiban (Disaggpro™ ) Clinical development CeleBrate trial results About us News Download Back
| A business type in JSON-LD | Organization |
| Name | CeleCor Therapeutics |
| Telephone | no |
| Address | no |
| Opening hours | no |
| Menu or price list | nothing |
| Cuisine in structured data | no |
| JSON-LD blocks | 1 (BreadcrumbList, EntryPoint, ImageObject, ListItem, Organization, PropertyValueSpecification) |
No booking or ordering link found. An agent has nothing to act on.
Everything here comes from one fetch of the homepage as a crawler; the report turns it into a score and fixes, with a kit to paste.